NL-OMON52345尚未招募2 期
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients with Advanced Solid Malignancies - MasterKey-01
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically- or cytologically-confirmed locally advanced or metastatic solid
- •tumor with documented recurrence or disease progression from standard
- •anticancer therapy in the advanced/metastatic setting;
- •No standard therapy available or standard therapy is considered unsuitable or
- •intolerable according to the Investigator and consultation with the Medical
- •Patients with a solid tumor harboring an:
- •a. Allosteric HER2 mutation
- •b. EGFR or HER2 exon 20 insertion mutation
- •as determined by a validated next-generation sequencing (NGS) test routinely
- •used by each institution using tissue and/or plasma. Eligible mutations are
- •summarized in Appendix I.
- •Eligible patients will be assigned to one of the 4 following cohorts:
- •Cohort 1: NSCLC with EGFR or HER2 exon 20 insertion mutation
- •Cohort 2: Breast cancer with an allosteric HER2 mutation and EGFR/HER2 exon 20
- •insertion mutations
- •Cohort 3: Any tumor (except breast) with an S310F/Y mutation
- •Cohort 4: Any other allosteric HER2 mutation and EGFR/HER2 exon 20 insertion
- •mutations not assigned to Cohorts 1-3;
- •Adequate archival tumor tissue or willing to undergo pretreatment biopsy;
- •Measurable disease according to RECIST version 1.1.
排除标准
- •Clinical laboratory values meeting the following criteria within 4 weeks (28
- •days) prior to baseline:
- •a. Serum creatinine >=1.5 × upper limit of normal (ULN) or calculated creatinine
- •clearance <=60 mL/min using Cockcroft-Gault equation
- •b. Total bilirubin >=1.5 × ULN or >=3.0 × ULN in the presence of documented
- •Gilbert*s syndrome
- •c. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >=2.5 ×
- •ULN, or AST or ALT >=5.0 × ULN in the presence of liver metastases
- •d. Hematologic function:
- •i. Absolute neutrophil count (ANC) <=1000 cells/µL
- •ii. Hemoglobin <=8.5 g/dL or 5.28 mmol/L
- •iii. Platelet count <=75,000/µL
- •Significant cardiovascular disease, including:
- •a. Cardiac failure New York Heart Association Class III or IV, or left
- •ventricular ejection fraction (LVEF) <50% or below the lower limit of the
- •Institution*s normal range
- •b. Myocardial infarction, severe or unstable angina within 6 months prior to
- •c. Significant thrombotic or embolic events within 3 months prior to baseline,
- •including, but not limited to, stroke or transient ischemic attack.
- •Catheter-related thrombosis and deep vein thrombosis are not a cause for
- •d. History or presence of any uncontrolled cardiovascular disease
- •e. Personal or family history of long QT syndrome
- •Electrocardiogram (ECG) findings obtained using the study site*s ECG
- •machine-derived measurements, meeting any of the following criteria:
- •a. Evidence of second- or third-degree atrioventricular block
- •b. Clinically significant arrhythmia (as determined by the Investigator)
- •c. QTc interval of >470 msec as calculated according to Fridericia*s formula
- •(QTcF = QT/R to R interval0.33)
- •Leptomeningeal or untreated and/or symptomatic central nervous system (CNS)
- •malignancies (primary or metastatic); patients with asymptomatic CNS metastases
- •who have undergone surgery or radiotherapy and who have been on a stable or
- •tapering dose of corticosteroids for at least 2 weeks prior to the first
- •scheduled day of dosing will be eligible for the trial
- •Women who are pregnant or breast-feeding
- •Taking or unable to discontinue proton pump inhibitors within 1 week prior to
- •Known concurrent KRAS mutation
- •Known tumor-harboring resistance mutations including EGFR T790M or C797S
- •mutations or HER2 C805S mutation
- •Prior documented treatment response (i.e., complete response [CR], partial
- •response [PR], or stable disease [SD] lasting >=24 weeks by RECIST v1.1) to
- •approved or investigational HER2 or EGFR therapies (e.g., afatinib, lapatinib,
- •dacomitinib,
- •neratinib, trastuzumab deruxtecan, poziotinib, mobocertinib, amivantamab)
- •a. Patients with or without tumor response discontinuing after 8 weeks or less
- •of therapy due to toxicity may be considered after discussion with the Sponsor
- •Medical Monitor
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid MalignanciesEUCTR2020-005492-12-DKBlack Diamond Therapeutics, Inc.619
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid Malignanciesung cancer, breast cancer, any other solid tumors with specific gene mutationsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-005492-12-NLBlack Diamond Therapeutics, Inc.100
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid MalignanciesEUCTR2020-005492-12-PLBlack Diamond Therapeutics, Inc.619
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid MalignanciesEUCTR2020-005492-12-ITBlack Diamond Therapeutics, Inc619
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid MalignanciesEUCTR2020-005492-12-ESBlack Diamond Therapeutics, Inc.100